Precigen (PGEN) & Its Rivals Head to Head Review

Precigen (NASDAQ:PGEN) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Precigen to related businesses based on the strength of its dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares Precigen and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Precigen Competitors	-9,054.31%	-198.21%	-30.53%

Valuation and Earnings

This table compares Precigen and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Precigen	$9.68 million	-$250.64 million	-6.67
Precigen Competitors	$689.46 million	$10.37 million	-10.05

Precigen’s competitors have higher revenue and earnings than Precigen. Precigen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

33.5% of Precigen shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Precigen has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Precigen’s competitors have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Precigen and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1	1	4	0	2.50
Precigen Competitors	9773	15031	45238	1571	2.54

Precigen presently has a consensus target price of $13.67, suggesting a potential upside of 96.93%. As a group, “Biotechnology” companies have a potential upside of 95.47%. Given Precigen’s higher probable upside, equities research analysts plainly believe Precigen is more favorable than its competitors.

Summary

Precigen beats its competitors on 7 of the 13 factors compared.

Precigen Company Profile

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.